Lilly Asia Ventures contributed funds to a $10m series B round for Impact Therapeutics, having previously participated in the company's 2014 series A.
China-based pharmaceutical company Impact Therapeutics raised $10m in a series B round yesterday featuring Lilly Asia Ventures, the regional corporate venturing subsidiary of pharmaceutical firm Eli Lilly.
The round included Guangzhou Yuexiu Industrial Investment Fund, the investment arm of conglomerate Guangzhou Yuexiu Group; Sungent Bioventure, a VC firm founded by life sciences industrial park Suzhou BioBay and Sungent Holding Group, a joint project between the governments of Singapore and China; China Summit Capital and Haibang Ventures.
Founded in 2009, Impact…